Adding or consolidating call centers Free chat sex pissing
I would now like to turn the call over to Kendra Adams, Senior Director, Investor and Public Relations. Good morning everyone and welcome to Agios' third quarter 2017 conference call.You could access slides for today’s call by going to the Investors section of our website, David Schenkein, our Chief Executive Officer, who will review key business updates and milestone for 2017; Dr.With significantly more patients and longer follow up ivosidenib continues to demonstrate terrible remissions for IDH1 and mutant patients with advanced AML.
Both Phase 1 frontline trials combining ivosidenib or enasidenib was 7 3 or VIDAZA have also been accepted for oral presentations.Early data from these Phase 1 trials reinforce ongoing efforts at Agios and Celgene to advance the IDH inhibitors into the newly diagnosed setting.In total three Agios led abstracts from our IDH program and one from PKR have been accepted for presentation at ASH.With the AG-348 pivotal design finalized the team is focused on global operational preparations to begin enrolling patients in the first half of 2018.In addition we are planning to initiate a global patient registry in pyruvate kinase deficiency to increase understanding of the long-term disease burden from this chronic anemia.
These data formed the core of the efficacy analysis for our planned NDA submission.